NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$34.84
+0.47 (+1.37%)
Close of Nov 06, 2026 · end-of-day data
PGNY 8-K filings in 2024
Every material Form 8-K Progyny filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Progyny reported third-quarter 2024 results on November 12, 2024. Revenue rose 2.0% to $286.6 million, but net income, gross margin and Adjusted EBITDA declined from a year earlier, and the company revised its full-year 2024 guidance lower. For shareholders, the revised outlook projects full-year 2024 revenue of $1.135 billion to $1.150 billion and net income of $49.9 million to $53.3 million, with the company citing unexpected variability in member treatment patterns.
Q3 2024 revenue rose 2.0% to $286.6 million, while net income fell to $10.4 million, or $0.11 per diluted share, from $15.9 million, or $0.16.
Gross margin fell to 20.7% from 22.3%, and Adjusted EBITDA was $46.5 million, down 7.1%.
Full-year 2024 revenue is now projected at $1.135 billion to $1.150 billion, and net income at $49.9 million to $53.3 million.
Fourth-quarter 2024 revenue is projected at $266.2 million to $281.2 million, or (1)% to 4% growth; a large client will not renew in 2025.
Progyny reported second-quarter 2024 revenue of $304.1 million, up 8.8%, with net income of $16.5 million and Adjusted EBITDA of $54.5 million, up 15%. The company said revenue per utilizing member is running below its expectations and revised its second-half outlook, now projecting full-year 2024 revenue of $1.165 billion to $1.20 billion. The board also authorized an additional $100 million share repurchase, which matters to shareholders because the outlook is softer even as profit and buybacks grew.
Q2 2024 revenue was $304.1 million, up 8.8%, and net income was $16.5 million, or $0.17 per diluted share, versus $0.15 a year earlier
Adjusted EBITDA was $54.5 million, up 15%, with an Adjusted EBITDA margin of 17.9%
Full-year 2024 revenue is now projected at $1.165 billion to $1.20 billion; third-quarter revenue is projected at $290.0 million to $303.0 million
On August 5, 2024, the board authorized an additional $100 million of share repurchases, after the company bought 5,593,128 shares for $159.8 million in the second quarter
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Progyny filing is on SEC EDGAR ↗. 8-K briefs of other companies →